Anti-Cancer Efficacy of Silybin Derivatives - A Structure-Activity Relationship

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Agarwal, Chapla ^a,b   Wadhwa, Ritambhara ^a   Deep, Gagan ^a,b   Biedermann, David ^c   Gažák, Radek ^c   Křen, Vladimír ^c   Agarwal, Rajesh ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c INSTITUTE OF MICROBIOLOGY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DEHYDROSILYBIN; 23 O PALMITOYLSILYBIN; 7 O GALLOYLSILYBIN; 7 O METHYLSILYBIN; 7 O PALMITOYLSILYBIN; 7,23 DISULPHATESILYBIN; FLAVONOLIGNAN; SILIBININ; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; ISOMER; RACEMIC MIXTURE; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; HCT116 CELLS; HUMANS; MALE; MOLECULAR STRUCTURE; SILYMARIN; STRUCTURE-ACTIVITY RELATIONSHIP;

RODENTIA; SILYBUM MARIANUM;

EID: 84875541201     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060074     Document Type: Article

References (38)

1. Agarwal R, Agarwal C, Ichikawa H, Singh RP, Aggarwal BB, (2006) Anticancer potential of silymarin: from bench to bed side. Anticancer Res 26: 4457-4498.
2. Pradhan SC, Girish C, (2006) Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res 124: 491-504.
3. Gazak R, Walterova D, Kren V, (2007) Silybin and silymarin-new and emerging applications in medicine. Curr Med Chem 14: 315-338.
4. Rainone F, (2005) Milk thistle. Am Fam Physician 72: 1285-1288.
5. Gyorgy I, Antus S, Blazovics A, Foldiak G, (1992) Substituent effects in the free radical reactions of silybin: radiation-induced oxidation of the flavonoid at neutral pH. Int J Radiat Biol 61: 603-609.
6. Basaga H, Poli G, Tekkaya C, Aras I, (1997) Free radical scavenging and antioxidative properties of 'silibin' complexes on microsomal lipid peroxidation. Cell Biochem Funct 15: 27-33.
7. Deep G, Agarwal R, (2010) Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev 29: 447-463.
8. Deep G, Agarwal R, (2007) Chemopreventive efficacy of silymarin in skin and prostate cancer. Integr Cancer Ther 6: 130-145.
9. Flaig TW, Glode M, Gustafson D, van Bokhoven A, Tao Y, et al. (2010) A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate 70: 848-855.
10. Flaig TW, Gustafson DL, Su LJ, Zirrolli JA, Crighton F, et al. (2007) A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs 25: 139-146.
11. Hoh C, Boocock D, Marczylo T, Singh R, Berry DP, et al. (2006) Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clin Cancer Res 12: 2944-2950.
12. Deep G, Agarwal R, (2010) Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer and Metastasis Reviews 29: 447-463.
13. Davis-Searles PR, Nakanishi Y, Kim NC, Graf TN, Oberlies NH, et al. (2005) Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Cancer Res 65: 4448-4457.
14. Deep G, Oberlies NH, Kroll DJ, Agarwal R, (2007) Isosilybin B and isosilybin A inhibit growth, induce G1 arrest and cause apoptosis in human prostate cancer LNCaP and 22Rv1 cells. Carcinogenesis 28: 1533-1542.
15. Deep G, Gangar SC, Rajamanickam S, Raina K, Gu M, et al. (2012) Angiopreventive efficacy of pure flavonolignans from milk thistle extract against prostate cancer: targeting VEGF-VEGFR signaling. PLoS One 7: e34630.
16. Kroll DJ, Shaw HS, Oberlies NH, (2007) Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther 6: 110-119.
17. Graf TN, Wani MC, Agarwal R, Kroll DJ, Oberlies NH, (2007) Gram-scale purification of flavonolignan diastereoisomers from Silybum marianum (Milk Thistle) extract in support of preclinical in vivo studies for prostate cancer chemoprevention. Planta Med 73: 1495-1501.
18. Trouillas P, Marsal P, Svobodova A, Vostalova J, Gazak R, et al. (2008) Mechanism of the antioxidant action of silybin and 2,3-dehydrosilybin flavonolignans: a joint experimental and theoretical study. J Phys Chem A 112: 1054-1063.
19. Gazak R, Sedmera P, Vrbacky M, Vostalova J, Drahota Z, et al. (2009) Molecular mechanisms of silybin and 2,3-dehydrosilybin antiradical activity-role of individual hydroxyl groups. Free Radic Biol Med 46: 745-758.
20. Gazak R, Purchartova K, Marhol P, Zivna L, Sedmera P, et al. (2010) Antioxidant and antiviral activities of silybin fatty acid conjugates. Eur J Med Chem 45: 1059-1067.
21. Gazak R, Valentova K, Fuksova K, Marhol P, Kuzma M, et al. (2011) Synthesis and antiangiogenic activity of new silybin galloyl esters. J Med Chem 54: 7397-7407.
22. Gazak R, Svobodova A, Psotova J, Sedmera P, Prikrylova V, et al. (2004) Oxidised derivatives of silybin and their antiradical and antioxidant activity. Bioorg Med Chem 12: 5677-5687.
23. Dzubak P, Hajduch M, Gazak R, Svobodova A, Psotova J, et al. (2006) New derivatives of silybin and 2,3-dehydrosilybin and their cytotoxic and P-glycoprotein modulatory activity. Bioorg Med Chem 14: 3793-3810.
24. Gazak R TP, Biedermann D, Fuksova K, Marhol P, Kuzma M, Kren V (2013) Base-catalyzed oxidation of silybin and isosilybin into 2,3-dehydro-derivatives. Tetrahedron Letters In press.
25. Monti D, Gazak R, Marhol P, Biedermann D, Purchartova K, et al. (2010) Enzymatic kinetic resolution of silybin diastereoisomers. J Nat Prod 73: 613-619.
26. Gažák R MP, Purchartová K, Monti D, Biedermann D, Riva S, Cvak L, Křen V, (2010) Large-scale separation of silybin diastereoisomers using lipases. Process Biochemistry 45: 1657-1663.
27. Sharma G, Singh RP, Chan DC, Agarwal R, (2003) Silibinin induces growth inhibition and apoptotic cell death in human lung carcinoma cells. Anticancer Res 23: 2649-2655.
28. Flaig TW, Gustafson DL, Su LJ, Zirrolli JA, Crighton F, et al. (2007) A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Investigational New Drugs 25: 139-146.
29. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
30. Deep G, Agarwal R, (2008) New combination therapies with cell-cycle agents. Curr Opin Investig Drugs 9: 591-604.
31. Tyagi AK, Singh RP, Agarwal C, Chan DC, Agarwal R, (2002) Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis. Clin Cancer Res 8: 3512-3519.
32. Dhanalakshmi S, Agarwal P, Glode LM, Agarwal R, (2003) Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin- and carboplatin-induced growth inhibition and apoptotic death. Int J Cancer 106: 699-705.
33. Flaig TW, Su LJ, Harrison G, Agarwal R, Glode LM, (2007) Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells. Int J Cancer 120: 2028-2033.
34. Tyagi AK, Agarwal C, Chan DC, Agarwal R, (2004) Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncol Rep 11: 493-499.
35. Scambia G, De Vincenzo R, Ranelletti FO, Panici PB, Ferrandina G, et al. (1996) Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin. Eur J Cancer 32A: 877-882.
36. Giacomelli S, Gallo D, Apollonio P, Ferlini C, Distefano M, et al. (2002) Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo the activity of cisplatin. Life Sci 70: 1447-1459.
37. Singh RP, Mallikarjuna GU, Sharma G, Dhanalakshmi S, Tyagi AK, et al. (2004) Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance. Clin Cancer Res 10: 8641-8647.
38. Deep G, Agarwal R (2012 (In press)) Targeting Tumor Microenvironment with Silibinin: Promise and Potential for a Translational Cancer Chemopreventive Strategy. Current cancer drug target.